 |
|
Should doctors be 'selling' drugs for the pharmaceutical industry?
June 20, 2008Feature: Key opinion leaders -- independent experts or drug representatives in disguise?
Are senior doctors who help drug companies sell their drugs independent experts or just drug representatives in disguise, asks Ray Moynihan from the University of Newcastle in Australia, in this week's BMJ.
Moynihan exposes the reality behind the practice with some candid revelations from industry insiders.
Pharmaceutical companies regularly sponsor leading specialists with "generous fees to peddle influence" and promote drugs to the profession and the public, writes Moynihan.
Drug companies will pay influential doctors up to $400 an hour to act as key opinion leaders, and some doctors earn more than $25 000 a year in advisory fees.
Kimberly Elliot, a former award-winning drug company sales representative interviewed* by Moynihan, reveals that drug companies desperately need key opinion leaders in order for doctors to believe what they are saying and prescribe their products, because drug representatives are often not believed. Essentially, she says, key opinion leaders are just salespeople.
So how independent are these doctors who have long term financial arrangements with drug companies?
According to Richard Tiner, medical director at the Association of the British Pharmaceutical Industry, although "the work might help to promote a particular medicine" it should be considered payment for work done, and not a bribe. The best antidote to concerns about independence would be more transparency-all company payments to speakers should be routinely disclosed at medical meetings, he adds.
But David Blumenthal, from Harvard University, believes that payments to key opinion leaders are not in the public interest or in the interests of the patients served by these doctors, and calls for a major cutback in industry influence over the medical profession and its education.
In an accompanying head to head, Charlie Buckwell, Chief Executive of the Complete Medical Group and Professor Giovannii Fava, from the University of Bologna, debate whether drug companies' use of medical experts is essential for medical advancement or whether it risks scientific integrity.
BMJ-British Medical Journal
Pharmaceutical companies regularly sponsor leading specialists with "generous fees to peddle influence" and promote drugs to the profession and the public, writes Moynihan.
Drug companies will pay influential doctors up to $400 an hour to act as key opinion leaders, and some doctors earn more than $25 000 a year in advisory fees.
Kimberly Elliot, a former award-winning drug company sales representative interviewed* by Moynihan, reveals that drug companies desperately need key opinion leaders in order for doctors to believe what they are saying and prescribe their products, because drug representatives are often not believed. Essentially, she says, key opinion leaders are just salespeople.
So how independent are these doctors who have long term financial arrangements with drug companies?
According to Richard Tiner, medical director at the Association of the British Pharmaceutical Industry, although "the work might help to promote a particular medicine" it should be considered payment for work done, and not a bribe. The best antidote to concerns about independence would be more transparency-all company payments to speakers should be routinely disclosed at medical meetings, he adds.
But David Blumenthal, from Harvard University, believes that payments to key opinion leaders are not in the public interest or in the interests of the patients served by these doctors, and calls for a major cutback in industry influence over the medical profession and its education.
In an accompanying head to head, Charlie Buckwell, Chief Executive of the Complete Medical Group and Professor Giovannii Fava, from the University of Bologna, debate whether drug companies' use of medical experts is essential for medical advancement or whether it risks scientific integrity.
BMJ-British Medical Journal
Drug Companies Current Events and Drug Companies News RSSLeptin's long-distance call to the pancreas
Rube Goldberg-the cartoonist who devised complex machines for simple tasks-would have smiled at one of leptin's mechanisms for curbing insulin release.
New study shows that a cough medicine ingredient could effectively treat prostate cancer
A study published today in the December issue of the European medical journal Anticancer Research demonstrates that an ingredient used in a common cough suppressant may be useful in treating advanced prostate cancer.
Credit crunch threatens new medicines
The global financial crisis could seriously delay the discovery and production of many new life-saving medicines, warns a major international conference today.
Study confirms benefit of combination therapy for Alzheimer's disease
Extended treatment with Alzheimer's disease drugs can significantly slow the rate at which the disorder advances, and combination therapy with two different classes of drugs is even better at helping patients maintain their ability to perform daily activities.
Risks and benefits of antipsychotics in children and adolescents
Many of the psychiatric disorders observed in adults have their onset in childhood or adolescence. In fact some studies show that at least 20% of children and adolescents will fulfil a diagnostic criterion for a mental disorder before reaching adulthood.
Breaking the 'mucus barrier' with a new drug delivery system
Chemical engineers from Johns Hopkins University have broken the "mucus barrier," engineering the first drug-delivery particles capable of passing through human mucus - regarded by many as nearly impenetrable - and carrying medication that could treat a range of diseases. Those conditions include lung cancer, cervical cancer and cystic fibrosis, the research noted in a presentation scheduled for the 236th National Meeting of the American Chemical Society.
Researchers create safer alternative to heparin
Robert Linhardt has spent years stitching together minuscule carbohydrates to build a more pure and safer alternative to the commonly used and controversial blood thinner heparin.
Researchers identify promising cancer drug target in prostate tumors
Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth.
New report: The truth about drug innovation
A new report co-authored by Manhattan Institute senior fellow Benjamin Zycher, and Joseph DiMasi, and Christopher-Paul Milne, researchers from the Tufts Center for the Study of Drug Development, examines case histories for thirty-five important pharmaceutical innovations.
Biomarkers identified for idiopathic pulmonary fibrosis
The first evidence of a distinctive protein signature that could help to transform the diagnosis and improve the monitoring of the devastating lung disease idiopathic pulmonary fibrosis (IPF) is being reported by University of Pittsburgh School of Medicine researchers in this month's edition of PLoS Medicine, an open-access journal of the Public Library of Science.
More Drug Companies Current Events and Drug Companies News Articles
 | The Truth About the Drug Companies: How They Deceive Us and What to Do About It by Marcia Angell During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless... |
 | The Truth About the Drug Companies: How They Deceive Us And What To Do About It by M.D. Marcia Angell Large Print. Written by the former editor in chief of 'The New England Journal of Medicine'. Winner of the Polk... |
 | Winning Legal Strategies for Food & Drug Companies:A Detailed Look at Regulations, Compliance, and Other Major Legal Issues (Inside the Minds) by Aspatore Books Staff Winning Legal Strategies for Food and Drug Companies is an authoritative, insider's perspective on the legal issues companies face in meeting FDA regulations. Featuring department heads, group chairs, and leading partners representing some of the nation's top firms, this book provides a broad, yet comprehensive overview of this highly-regulated practice area. From gaining FDA approval for a... |
 | Over Dose: The Case Against the Drug Companies: Prescription Drugs, Side Effects, and Your Health by Jay S. Cohen In late 1999, a headline in the New York Times read "Too Much of Good Thing? Doctor Challenges Drug Manual." The article described Dr. Jay S. Cohen's new report maintaining that the recommended doses in the Physicians' Desk Reference are too high for many people and are causing a slew of unnecessary adverse reactions, "ranging from dizziness and nausea all the way to death." Drug reactions in... |
 | Natural Secrets Drug Companies Don't Want You to Know About by Mark A. Stevens with Christine Jones Do you believe that aging and sickness are a natural part of life? What if you could feel better, look younger, and live longer without relying on expensive prescription drugs fraught with potentially dangerous side effects? Imagine waking up each morning with a zest for life and the energy to pursue it to its fullest. It is possible to restore and maintain good health while slowing or even... |
 | Monkeys in the Middle: How One Drug Company Kept a Parkinsons Disease Breakthrough Out of Reach by Nick Nelson Some said it was a miracle drug; others called it the cure. A drug known simply as "GDNF" seemed to do the impossible by actually reversing the effects of Parkinson's disease. The miracle ended in the fall of 2004 when Amgen Inc. abruptly halted clinical trials of GDNF and denied access to the drug. In "Monkeys in the Middle", investigative reporter Nick Nelson recounts the true story of the... |
| Bad Company: Drugs, Hollywood, and the Cotton Club Murder (True Crime Library) by Steve Wick Seductive Laney Jacobs introduced legendary producer Bob Evans (Chinatown and The Godfather) to entrepreneur Roy Radin with the expectation of becoming a partner on a big movie deal. But when Radin disagreed, he was murdered. Includes new update covering Jacobs' conviction. LG Selection. Photographs. Movie rights optioned by ITC and Norman Wright. HC: Harcourt Brace... | |
| Amazing Medicines the Drug Companies Don't Want You to Discover by University Medical Research | |
 | Managing Relationships with Industry: A Physician's Compliance Manual by Steven C. Schachter, William Mandell, Scott Harshbarger, Randall Grometstein Physicians in academic and private practice settings are increasingly engaged in collaborations and encounters with employees and contractors from the research and marketing arms of pharmaceutical and device companies. These activities are numerous and range from consulting and conducting research, to giving talks, meeting with sales representatives, to interfacing with industry on behalf of... |
 | Dispensing with the Truth: The Victims, the Drug Companies, and the Dramatic Story Behind the Battle over Fen-Phen by Alicia Mundy In 1996, a terrible epidemic began. Thousands of young women were stricken and many of them died. Some died quickly, within a few months; others lasted a couple of years. Many of those who didn't die suffered damage to their hearts and lungs, much of it permanent. Doctors suspected what the killer was. So did the Food and Drug Administration. The culprit was one-half of the most popular diet... |
| © 2009 BrightSurf.com |